MarginsXMarginsX
Home › Markets › Health Care › CRIS

Curis Inc. (CRIS)

CRIS trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.4358
-2.07% on the day
Market cap
$4.1M
Nano cap
Revenue · 2025
$9.4M
-13.4% on 2024
Net income · 2025
-$7.6M
-80.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1108205/000110820526000043/0001108205-26-000043-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerCRIS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001108205
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$9.4M
Net income-$7.6M
Operating income-$5.7M
Net margin-80.3%
Operating margin-60.5%
Revenue growth-13.4%
Cash$5.1M
Total assets$20.0M
P/E (computed)Net income was not positive
P/S (computed)0.4×

Warning signs

Cash runway
2.0 months
$5.1M cash at June 30, 2026
Share count, 1 year
+1371.5%
2025-11-04 to 2026-11-10 · +3133.8% over 3 years
Going-concern doubt
Yes
10-Q filed November 13, 2026
Insider net buying, 12 months
$6K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"In accordance with Financial Accounting Standards Board ( FASB ) Accounting Standards Update ( ASU ) No. 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40), the Company has concluded there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the "
10-Q 2026-11-13
Cash and burn$5.1M cash; operating cash flow -$7.6M a quarter.Report 2026-06-30
Shares outstanding9,512,232 (2026-11-10); 12,928,853 a year earlier; 5,883,063 three years earlier. 1y figure adjusted for splits (1-for-20 overall); 3y figure adjusted for splits (1-for-20 overall).Cover page 2026-11-10
Reverse splits, 3 years1; latest 1-for-20 on 2026-07-06Source 2026-07-06
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-11-13
Exchange deficiency notices, 12 months2 (8-K item 3.01)8-K 2026-11-06
AuditorPricewaterhouseCoopers LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-04-01
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $6K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$0-$8.6M-$9.6M$5.1MNo debt tags$4.3M10-Q 2026-08-14
Q1 2026
2026-03-31
$0-$24.2M-$9.0M$15.0MNo debt tags$7.1M10-Q 2026-05-13
Q4 2025
2025-12-31
$1.1M$19.4M-$6.4M$5.1M$0$9.4M10-K 2026-03-24
Q3 2025
2025-09-30
$3.2M-$7.7M-$5.6M$9.1M$7.0M$11.7M10-Q 2025-11-06
Q2 2025
2025-06-30
$2.7M-$8.6M-$8.0M$10.1M$7.4M$11.4M10-Q 2026-08-14
Q1 2025
2025-03-31
$2.4M-$10.6M-$7.3M$20.3M$7.2M$11.2M10-Q 2026-05-13
Q4 2024
2024-12-31
$3.3M-$9.6M-$9.3M$20.0M$7.6M$10.9M10-K 2026-03-24
Q3 2024
2024-09-30
$2.9M-$10.1M-$5.9M$20.9MNo debt tags$10.3M10-Q 2025-11-06

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM S-3
S-32026-11-13
Latest annual report10-K2026-03-24
Latest quarterly / interim10-Q2026-11-13
Latest current report
FORM 8-K
8-K2026-11-13
Latest proxyDEF 14A2026-11-02

Source: SEC EDGAR submissions feed, 1,029 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-50.5%
1 month-26.2%
3 months-75.9%
Year to date-97.7%
1 year-98.0%
From 52-week high-98.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
LIMNLiminatus Pharma Inc.$2.97-0.67%$4.0M
BTTCBlack Titan Corporation$0.2873-9.20%$4.3M
CELZCreative Medical Technology Holdings Inc.$0.5201-1.51%$4.0M
AIMAIM ImmunoTech Inc.$0.1310-8.77%$5.2M
SNTISenti Biosciences Holdings Inc.$0.1360-2.86%$5.2M
VIVSVivoSim Labs Inc.$0.1237-2.68%$2.5M
CLDICalidi Biotherapeutics Inc.$0.6023-3.15%$2.2M
INABIN8bio Inc.$0.8160-0.49%$8.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier